Arcadia biosciences, inc. (RKDA)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Revenues:
Total revenues

309

416

392

203

158

444

370

436

214

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses (income):
Total revenues

-

-

-

-

-

-

-

-

-

-

589

991

-

-

-

-

-

-

-

-

-

-

-

-

-

Product

-

-

-

-

-

-

-

-

-

-

-

-

205

247

102

65

255

83

123

179

81

89

67

65

134

License

-

-

-

-

-

-

-

-

-

-

-

-

106

-366

218

140

152

443

214

401

158

1,863

91

195

176

Contract research and government grants

-

-

-

-

-

-

-

-

-

-

-

-

707

659

755

516

445

820

1,486

850

576

846

1,344

1,045

1,067

Total revenues

-

-

-

-

-

-

-

-

-

-

-

-

1,018

540

1,075

721

852

1,346

1,823

1,430

815

2,798

1,502

1,305

1,377

Operating expenses:
Cost of product revenues

-

-

-

-

-

-

-

-

-

-

-

-

106

653

60

35

147

669

61

106

56

65

1,795

46

91

Research and development

2,244

1,712

1,931

1,950

1,505

1,545

1,334

1,794

1,396

2,166

1,749

1,669

1,823

1,990

2,255

2,216

2,202

1,869

3,179

2,086

1,832

2,070

3,684

2,275

1,983

Selling, general and administrative

3,723

3,133

4,477

3,145

2,812

3,023

3,011

2,949

2,621

2,241

2,415

2,943

3,052

3,368

2,687

2,759

3,436

2,878

2,818

2,785

2,638

2,292

1,966

3,983

1,885

Total operating expenses

6,099

4,405

6,585

5,184

4,376

4,798

4,469

5,014

4,053

4,428

4,204

4,728

4,981

6,011

5,002

5,010

5,785

5,416

6,058

4,977

4,526

4,427

7,445

6,304

3,959

Loss from operations

-5,790

-3,989

-6,193

-4,981

-4,218

-4,354

-4,099

-4,578

-3,839

-3,000

-3,615

-3,737

-3,963

-5,471

-3,927

-4,289

-4,933

-4,070

-4,235

-3,547

-3,711

-1,629

-5,943

-4,999

-2,582

Interest expense

3

-

3

-

-

-

-

-

-

0

43

365

339

334

331

327

327

650

766

775

467

346

265

399

384

Other income, net

72

126

119

101

120

128

134

94

38

35

46

104

96

98

90

76

76

897

285

735

-1,396

15

-813

222

-21

Initial loss on common stock warrant and common stock adjustment feature liabilities

-

-

-

-

-

0

0

0

4,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of common stock warrant liabilities

-8,161

2,453

7,777

-9,482

8,495

-3,575

-8,421

535

1,900

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Offering costs

-

-

336

365

-

11

1

1,639

904

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

-900

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) before income taxes

2,440

-6,325

-14,190

4,237

-12,593

-662

4,455

-6,658

-10,605

-

-4,512

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

-3,998

-4,206

-5,707

-4,168

-4,540

-5,184

-4,053

-4,716

-3,587

-5,574

-

-

-

-

Net loss before income taxes and equity in loss of unconsolidated entity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,960

-7,021

-5,176

-2,987

Income tax provision

17

-13

-3

-1

19

-16

5

11

10

-5

13

8

10

1

7

11

6

-196

-97

90

229

28

43

99

93

Net income (loss)

2,423

-

-

-

-12,612

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss attributable to non-controlling interest

-102

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Equity in loss of unconsolidated entity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-536

-396

Net income (loss) attributable to common stockholders

2,525

-6,244

-14,187

4,238

-12,612

-646

4,450

-6,669

-10,615

-2,960

-4,525

-4,006

-4,216

-5,708

-4,175

-4,551

-5,190

-3,857

-4,619

-3,677

-5,803

-1,988

-7,064

-5,811

-3,476

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

879

1,695

-

1,570

518

-

Deemed dividends to warrant holder

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

197

-

-

-

-

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,857

-4,619

-4,556

-7,695

-3,638

-8,634

-6,329

-3,476

Net income (loss) per share attributable to common stockholders:
Basic and diluted

0.29

-0.69

-2.04

0.84

-2.64

2.37

0.93

-2.02

-4.86

-1.38

-2.12

-1.88

-1.90

-8.54

-0.09

-0.10

-0.12

3.28

-0.11

-0.19

-3.71

-1.75

-4.19

-3.08

-1.69

Weighted-average number of shares used in per share calculations:
Basic

8,651

-

-

-

4,776

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted

8,674

-

-

-

4,776

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and diluted

-

-

6,942

5,054

-

4,797

4,774

3,307

2,186

2,139

2,133

2,133

2,218

-124,020

44,370

44,308

44,215

44,738

43,647

23,775

2,075

2,070

2,061

2,056

2,056

Other comprehensive loss, net of tax
Unrealized losses on available-for-sale securities

-1

-

-1

-

-

-

-2

0

1

4

8

7

-1

-12

-1

25

84

-

-

-

-

-

-

-

-

Other comprehensive loss

-1

-

-1

-

-

-

-2

0

1

4

8

7

-1

-12

-1

25

84

-

-

-

-

-

-

-

-

Comprehensive income (loss) attributable to common stockholders

2,524

-6,242

-14,188

4,238

-12,612

-645

4,448

-6,669

-10,614

-2,956

-4,517

-3,999

-4,217

-5,720

-4,176

-4,526

-5,106

-3,972

-4,619

-4,556

-7,695

-

-

-

-

Product
Total revenues

154

329

216

162

107

264

144

188

61

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of product revenues

132

560

177

89

59

230

124

271

36

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

License
Total revenues

100

-

17

-

-

-

10

90

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Royalty
Total revenues

30

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contract Research And Government Grants
Total revenues

25

37

159

41

51

130

216

158

153

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-